Parkinson Disease Neuroprotection Clinical Trial

帕金森病神经保护临床试验

• 批准号: 6797312
• 负责人: ROBERT W HAMILL
• 金额: $ 3.03万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6797312
• 关键词: Parkinson' s disease; chemoprevention; clinical research; cooperative study; data management; experimental designs; human subject; human therapy evaluation; medical outreach /case finding; nervous system disorder chemotherapy; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): The NINDS seeks to establish Clinical Trial Sites that will collaborate and cooperate in the development and testing of new approaches to neuroprotection therapy. The Neurology programs at the University of Vermont College of Medicine (UVM/COM), the Dartmouth Hitchcock Medical Center (DHMC), and Maine Neurology (Maine Medical Center) will work together in order to establish a Northern New England Clinical Trials Center (NNE-CTC). Specifically, the aims of the NNE-CTC are:To recruit and follow subjects with early Parkinson's disease (PD) for a randomized clinical trial of Neuroprotection in PD;To provide high quality clinical assessment, and data entry and management, and to meet all regulatory statutes outlined for experimental neurotherapeutics;To evolve new approaches to interventional therapy and assessment strategies as permitted within the structure of the Center and overall project;To fully integrate our Clinical Center into the operation of the NINDS sponsored Neuroprotection Trial program and to fully cooperate with all aspects of the trial.In addition to these specific aims, an overall goal of the NNE-CTC is to bring opportunities for the citizens of Northern New England and Upstate New York to participate in the evolving therapies for neurodegenerative disorders.

描述(由申请人提供)：NINDS寻求建立临床试验站点，在开发和测试神经保护治疗的新方法方面进行合作和合作。佛蒙特大学医学院(UVM/COM)、达特茅斯·希区柯克医学中心(DHMC)和缅因州神经病学(缅因州医学中心)的神经学项目将合作建立新英格兰北部临床试验中心(NNE-CTC)。具体地说，NNE-CTC的目标是：招募和跟踪早期帕金森病(PD)患者，进行PD神经保护的随机临床试验；提供高质量的临床评估、数据输入和管理，并满足所有为实验神经疗法概述的法规；在中心结构和整体项目允许的情况下，发展介入治疗和评估策略的新方法；将我们的临床中心完全整合到NINDS赞助的神经保护试验计划的运作中，并与试验的所有方面充分合作。除了这些具体目标外，NNE-CTC的一个总体目标是为新英格兰北部和纽约州北部的公民带来参与神经退行性疾病不断发展的治疗方法的机会。